Table 2.

Changes in radiographic scores from month 12 to month 24 in patients receiving tofacitinib who completed month 12^a

	Tofacitinib 5 mgtwice daily(n = 263)	Tofacitinib 10 mgtwice daily (n = 264)
SHS	0.19 ± 1.04	0.15 ± 1.23
Erosion score	0.00 ± 0.49	−0.04 ± 0.59
JSN score	0.18 ± 0.83	0.19 ± 0.96

^aValues are the mean ± SD change from month 12 to month 24. Treatment groups included patients who received the indicated dosage of tofacitinib from the beginning of the study and patients who received the indicated dosage of tofacitinib after switching from placebo. All patients received background methotrexate. Data are observed (no imputation). SHS = modified Sharp/van der Heijde score; JSN = joint space narrowing.